{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:01:59Z","timestamp":1793037719101,"version":"4.5.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.purol.2022.07.147","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T21:55:31Z","timestamp":1668549331000},"page":"1373-1419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-2152","authenticated-orcid":false,"given":"G.","family":"Ploussard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-B.","family":"Beauval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gauth\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rozet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ruffion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.purol.2022.07.147_bib0715","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0090-4295(00)00793-7","article-title":"Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making","volume":"56","author":"Oefelein","year":"2000","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib0720","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2015.04.023","article-title":"Survivorship and improving quality of life in men with prostate cancer","volume":"68","author":"Bourke","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.147_bib0725","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2015.10.047","article-title":"Exercise for men with prostate cancer: a systematic review and meta-analysis","volume":"69","author":"Bourke","year":"2016","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.purol.2022.07.147_bib0730","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2014.60.2557","article-title":"Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement","volume":"33","author":"Resnick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib0735","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/jbmr.1771","article-title":"Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy","volume":"28","author":"Greenspan","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib0740","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","article-title":"Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer","volume":"69","author":"Morote","year":"2007","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib0745","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbspin.2018.09.017","article-title":"French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation","volume":"86","author":"Briot","year":"2019","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib0750","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","article-title":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial","volume":"11","author":"Irani","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib0755","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1464-410X.2006.06176.x","article-title":"Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer","volume":"98","author":"Mottet","year":"2006","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.purol.2022.07.147_bib0760","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41391-021-00406-4","article-title":"Exercise medicine in men with prostate cancer: breaking barriers to increase participation","volume":"24","author":"Galvao","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib0765","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1017\/S1041610296002724","article-title":"Utilization of the Draw a Person Test in the elderly","volume":"8","author":"Clement","year":"1996","journal-title":"Int Psychogeriatr"},{"issue":"10","key":"10.1016\/j.purol.2022.07.147_bib0770","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1532-5415.2003.51465.x","article-title":"The Mini-Cog as a screen for dementia: validation in a population-based sample","volume":"51","author":"Borson","year":"2003","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib0775","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.purol.2022.07.147_bib0780","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2003-031069","article-title":"The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men","volume":"89","author":"Malkin","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.purol.2022.07.147_bib0785","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.purol.2022.07.147_bib0790","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)","volume":"158","author":"Maluf","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.purol.2022.07.147_bib0795","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-022-00533-6","article-title":"LHRH sparing therapy in patients with chemotherapy-naive, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial","author":"Ohlmann","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"10.1016\/j.purol.2022.07.147_bib0800","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41416-018-0123-9","article-title":"Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)","volume":"119","author":"Romero-Laorden","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib1425","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol"},{"issue":"10024","key":"10.1016\/j.purol.2022.07.147_bib0810","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.purol.2022.07.147_bib0815","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"9768","key":"10.1016\/j.purol.2022.07.147_bib0820","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib0825","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"issue":"9810","key":"10.1016\/j.purol.2022.07.147_bib0830","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib0835","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.purol.2022.07.147_bib0840","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib0845","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.purol.2022.07.147_bib0850","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.147_bib0855","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Benesova","year":"2015","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib0860","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.semnuclmed.2019.07.003","article-title":"PSMA-based theranostics: a step-by-step practical approach to diagnosis and therapy for mCRPC patients","volume":"50","author":"Ahmadzadehfar","year":"2020","journal-title":"Semin Nucl Med"},{"issue":"12","key":"10.1016\/j.purol.2022.07.147_bib0865","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.purol.2022.07.147_bib0870","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.purol.2022.07.147_bib0875","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib0880","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German Multicenter Study Investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.purol.2022.07.147_bib0885","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.purol.2022.07.147_bib0890","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2967\/jnumed.118.216820","article-title":"Clinical Outcomes of (177)Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy","volume":"60","author":"Barber","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.purol.2022.07.147_bib0895","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib0900","first-page":"40","article-title":"Randomized, Double-Blind","volume":"35","author":"Beer","year":"2017","journal-title":"Phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol"},{"issue":"7","key":"10.1016\/j.purol.2022.07.147_bib0905","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.147_bib0910","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.07.147_bib0915","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/PO.19.00399","article-title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase Inhibitors, and PD-1 inhibitors","volume":"4","author":"Antonarakis","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib0920","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.purol.2022.07.147_bib0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 Trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell."},{"issue":"24","key":"10.1016\/j.purol.2022.07.147_bib0930","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.purol.2022.07.147_bib0935","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/jcm11061734","article-title":"PARP Inhibitors as monotherapy in daily practice for advanced prostate cancers","volume":"11","author":"Teyssonneau","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib0940","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.purol.2021.12.007","article-title":"[DNA repair gene alterations testing in prostate cancer: a practical update by the prostate cancer committee of the french association of urology]","volume":"32","author":"Ploussard","year":"2022","journal-title":"Prog Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib0945","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.purol.2022.07.147_bib0950","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib0955","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized Phase II Study Evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN Loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10295","key":"10.1016\/j.purol.2022.07.147_bib0960","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib0965","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/jcm11010160","article-title":"Overview of the development and use of akt inhibitors in prostate cancer","volume":"11","author":"Gasmi","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.purol.2022.07.147_bib0970","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.purol.2022.07.147_bib0975","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.purol.2022.07.147_bib0980","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.purol.2022.07.147_bib0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.12.009","article-title":"Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing definitions of CHAARTED and LATITUDE trial","volume":"36","author":"Buelens","year":"2018","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib0990","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.31860","article-title":"Oligometastatic prostate cancer: reality or figment of imagination?","volume":"125","author":"Foster","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib0995","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.purol.2022.07.147_bib1000","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib1005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.147_bib1010","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH Agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"202","author":"Margel","year":"2019","journal-title":"J Urol"},{"issue":"16","key":"10.1016\/j.purol.2022.07.147_bib1015","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.purol.2022.07.147_bib1020","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.purol.2022.07.147_bib1025","article-title":"Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer","volume":"2014","author":"Kunath","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"9214","key":"10.1016\/j.purol.2022.07.147_bib1030","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials","volume":"355","author":"Prostate Cancer Trialists\u2019 Collaborative Group","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib1035","first-page":"3506","article-title":"Early versus deferred androgen suppression in the treatment of advanced prostatic cancer","author":"Nair","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"10.1016\/j.purol.2022.07.147_bib1040","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib1045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1200\/JCO.2015.62.8065","article-title":"Evaluating intermittent androgen-deprivation therapy phase III clinical trials: the devil is in the details","volume":"34","author":"Hussain","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.purol.2022.07.147_bib1050","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaoncol.2015.2895","article-title":"Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"1","author":"Magnan","year":"2015","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.purol.2022.07.147_bib1055","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib1060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2012.07.040","article-title":"Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects","volume":"63","author":"Salonen","year":"2013","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.purol.2022.07.147_bib1065","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib1070","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized Phase 3 GETUG-AFU15 Trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"issue":"10024","key":"10.1016\/j.purol.2022.07.147_bib1075","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.purol.2022.07.147_bib1080","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib1085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.147_bib1090","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.147_bib1095","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib1100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.purol.2022.07.147_bib1105","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.purol.2022.07.147_bib1110","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib1115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.purol.2022.07.147_bib1120","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.purol.2022.07.147_bib1125","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10336","key":"10.1016\/j.purol.2022.07.147_bib1130","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.purol.2022.07.147_bib1135","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib1140","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boeve","year":"2019","journal-title":"Eur Urol"},{"issue":"10162","key":"10.1016\/j.purol.2022.07.147_bib1145","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.purol.2022.07.147_bib1150","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10185","key":"10.1016\/j.purol.2022.07.147_bib1155","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.purol.2022.07.147_bib1160","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.147_bib1165","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.purol.2022.07.147_bib1170","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.21.00728","article-title":"Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE Trial","volume":"40","author":"Rush","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib1175","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.purol.2022.07.147_bib1180","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer","volume":"25","author":"Fendler","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.purol.2022.07.147_bib1185","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.purol.2022.07.147_bib1190","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.purol.2022.07.147_bib1195","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.purol.2022.07.147_bib1200","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.purol.2022.07.147_bib1205","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.purol.2022.07.147_bib1210","article-title":"Health-related quality of life at the SPARTAN final analysis of apalutamide for nonmetastatic castration-resistant prostate cancer patients receiving androgen deprivation therapy","volume":"31","author":"Oudard","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.purol.2022.07.147_bib1215","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2021.06.010","article-title":"Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial","volume":"154","author":"Smith","year":"2021","journal-title":"Eur J Cancer"},{"issue":"23","key":"10.1016\/j.purol.2022.07.147_bib1220","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.3390\/cancers13235872","article-title":"The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials","volume":"13","author":"Tombal","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.purol.2022.07.147_bib1225","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.purol.2022.07.147_bib1230","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.purol.2022.07.147_bib1235","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib1240","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.147_bib1245","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib1250","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","volume":"17","author":"Shore","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.147_bib1255","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2016.07.027","article-title":"Impact of enzalutamide compared with bicalutamide on quality of life in men with metastatic castration-resistant prostate cancer: additional analyses from the TERRAIN randomised clinical trial","volume":"71","author":"Heidenreich","year":"2017","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.purol.2022.07.147_bib1260","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","article-title":"Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE Trial","volume":"34","author":"Penson","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.purol.2022.07.147_bib1265","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","article-title":"Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment","volume":"36","author":"Attard","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.purol.2022.07.147_bib1270","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib1275","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib1280","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.purol.2022.07.147_bib1285","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.purol.2022.07.147_bib1290","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20mg\/m(2)) and the currently approved dose (25mg\/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.purol.2022.07.147_bib1295","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.purol.2022.07.147_bib1300","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.purol.2022.07.147_bib1305","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ejca.2015.06.128","article-title":"Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer","volume":"51","author":"Loriot","year":"2015","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.purol.2022.07.147_bib1310","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/iju.13346","article-title":"Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-na\u00efve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration","volume":"24","author":"Terada","year":"2017","journal-title":"Int J Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.147_bib1315","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1016\/j.clgc.2016.12.015","article-title":"Comparative assessment of efficacies between 2\u00a0alternative therapeutic sequences with novel\u00a0androgen receptor-axis-targeted agents\u00a0in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer","volume":"15","author":"Miyake","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib1320","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clgc.2017.09.008","article-title":"Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"16","author":"Matsubara","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"10.1016\/j.purol.2022.07.147_bib1325","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.purol.2022.07.147_bib1330","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3390\/jcm8081251","article-title":"Comparison of radiographic progression-free survival and PSA response on sequential treatment using abiraterone and enzalutamide for newly diagnosed castration-resistant prostate cancer: a propensity score matched analysis from multicenter cohort","volume":"8","author":"Komura","year":"2019","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.purol.2022.07.147_bib1335","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.eururo.2017.09.022","article-title":"Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-na\u00efve prostate cancer in the GETUG-AFU 15 phase 3 trial","volume":"73","author":"Lavaud","year":"2018","journal-title":"Eur Urol"},{"issue":"9747","key":"10.1016\/j.purol.2022.07.147_bib1340","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.purol.2022.07.147_bib1345","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.purol.2022.07.147_bib1350","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.eururo.2018.01.010","article-title":"Clinical outcome of prostate cancer patients with germline dna repair mutations: retrospective analysis from an international study","volume":"73","author":"Mateo","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.07.147_bib1355","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","author":"de Bono","year":"2020","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib1360","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(22)00017-1","volume":"23","author":"Thiery-Vuillemin","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.purol.2022.07.147_bib1365","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.purol.2022.07.147_bib1370","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2017.12.012","article-title":"Loco-regional treatment for castration-resistant prostate cancer: is there any rationale?. A critical review from the AFU-GETUG","volume":"122","author":"Beauval","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.purol.2022.07.147_bib1375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.purol.2022.07.147_bib1380","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S1470-2045(14)70018-X","article-title":"Management of prostate cancer in older patients: updated recommendations of a working goup of the International Society of Geriatric Oncology","volume":"15","author":"Droz","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.147_bib1385","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2010.30.2075","article-title":"Impact of age at diagnosis on prostate cancer treatment and survival","volume":"29","author":"Bechis","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.purol.2022.07.147_bib1390","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","article-title":"20-year outcomes following conservative management of clinically localized prostate cancer","volume":"293","author":"Albertsen","year":"2005","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.purol.2022.07.147_bib1395","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.eururo.2015.03.021","article-title":"Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate cancer","volume":"68","author":"Lu-Yao","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib1400","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.purol.2022.07.147_bib1405","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.canep.2018.07.007","article-title":"Incidence of prostate cancer and net survival by grade in a geriatric population: a population-based study in a French administrative entity from 1991 to 2013","volume":"56","author":"Bellier","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"10","key":"10.1016\/j.purol.2022.07.147_bib1410","doi-asserted-by":"crossref","first-page":"709","DOI":"10.7326\/0003-4819-158-10-201305210-00005","article-title":"Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer","volume":"158","author":"Daskivich","year":"2013","journal-title":"Ann Intern Med"},{"issue":"Suppl 3","key":"10.1016\/j.purol.2022.07.147_bib1415","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bju.14228","article-title":"Localised prostate cancer in elderly men aged 80-89\u00a0years, findings from a population-based registry","volume":"121","author":"Vatandoust","year":"2018","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib1420","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.12.026","article-title":"Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer","volume":"68","author":"Bratt","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.07.147_bib1430","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10010152","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","author":"Anastasilakis","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.purol.2022.07.147_bib1435","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.34018","article-title":"Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)","volume":"151","author":"James","year":"2022","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.purol.2022.07.147_bib1440","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.purol.2022.07.147_bib1445","first-page":"3","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"9","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"10276","key":"10.1016\/j.purol.2022.07.147_bib1450","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708722003438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708722003438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:38:20Z","timestamp":1761115100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708722003438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":147,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1166708722003438"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2022.07.147","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2022.07.147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}